Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885102 | 0.79 | NCF1 (0.32) | NCF1 | |
| SCHEMBL1638324 | 0.72 | NCF1 (0.38) | NCF1SMPD3 | |
| SCHEMBL315179 | 0.72 | POLB (0.33) | — | |
| SCHEMBL1638184 | 0.72 | — | — | |
| SCHEMBL1464459 | 0.72 | — | — | |
| SCHEMBL17529634 | 0.71 | — | — | |
| SCHEMBL17529617 | 0.71 | — | — | |
| SCHEMBL22836535 | 0.71 | — | — | |
| SCHEMBL1637749 | 0.71 | MEN1 (0.36) | NCF1SMPD3 | |
| SCHEMBL9100785 | 0.67 | HSD17B10 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1554258-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2004018437-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | NCF1 3475/4885SMPD3 3577/4885 |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | NCF1 3475/4885SMPD3 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.